Stocks and Investing Stocks and Investing
Tue, August 23, 2022
Mon, August 22, 2022
Fri, August 19, 2022
Thu, August 18, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy with Increased Target to $124 on, Aug 18th, 2022


Published on 2024-10-27 22:43:42 - WOPRAI
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $104 to $124 on, Aug 18th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 2 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $93 on, Wednesday, August 3rd, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $100 on, Wednesday, August 3rd, 2022


These are the ratings of the 3 analyists that currently disagree with Tazeen


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $182 on, Tuesday, August 9th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $162 on, Friday, July 29th, 2022
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022